

**Academic Curriculum****PERSONAL INFORMATION**

First name, Family name: Luigino Calzetta

Researcher unique identifiers: ORCID 0000-0003-0456-069X, Research ID K-4516-2016; Scopus Author ID 26633652400

Date of birth: 11/03/1976

Nationality: Italy

URL for web site: <http://directory.uniroma2.it/index.php/chart/dettagliDocente/11029>

**• EDUCATION**

- 2012 PhD, Sackler Institute of Pulmonary Pharmacology, Pharmaceutical Science Research Division, King's College London, London, UK. PhD Supervisor: prof. Clive Page
- 2009 MPhil, Sackler Institute of Pulmonary Pharmacology, Pharmaceutical Science Research Division, King's College London, London, UK. PhD Supervisor: prof. Clive Page
- 2006 Postgraduate Degree, Animal Health, Breeding and Livestock Production, School of Veterinary Medicine, University of Teramo, Italy
- 2001 DVM degree, School of Veterinary Medicine, University of Teramo, Italy

**• CURRENT POSITIONS**

- 2020 – today RTD-B 06/D1 MED/10, Department of Medicine and Surgery, University of Parma, Italy
- 2008 – today Head of the Laboratory Respiratory Clinical Pharmacology, School of Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
- 2013 – today Honorary Researcher affiliate staff, Sackler Institute of Pulmonary Pharmacology, Pharmaceutical Science Research Division, King's College London, London (UK)
- 2010 – 2016 Farm Animal models medical-scientific consultant, Laboratory Animal Center, Centro Interdipartimentale Stazione per la Tecnologia Animale (STA), University of Rome "Tor Vergata", Rome, Italy
- 2010 – 2016 Clinical Trial Monitor, Coordinator and data analysis, Ockham Biotech Limited, Swanwick, Hampshire, UK

**• PREVIOUS POSITIONS**

- 2011 – 2014 Researcher, Laboratory of Systems Approaches and Non Communicable Diseases, IRCCS San Raffaele Pisana, Rome, Italy
- 2010 – 2013 Clinical Trial Monitor, Coordinator and data analysis, Verona Pharma PLC, London, UK
- 2010 – 2011 Scientific consultant, MIR Medical International Research S.r.l., Rome, Italy
- 2010 – 2011 Scientific consultant, Metaphora S.r.l., Rome, Italy
- 2010 Scientific consultant, Boehringer Ingelheim Italia SpA, Milan, Italy
- 2008-2009 Scientific consultant, Pneumolabs UK Limited, Harrow, UK
- 2008-2010 Scientific and clinical consultant, Veterinary Clinic Appia 24h, Rome, Italy
- 2005-2007 Researcher, Biotechnology Centre, Cardarelli Hospital, Naples, Italy

**• FELLOWSHIPS**

- 2014 – today 4<sup>th</sup> level (highest level; topic: respiratory pharmacology, veterinary pharmacology, meta-analyses) research grant, School of Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
- 2013 – 2014 Scholarship (topic: Search for novel early biomarkers for the detection of subjects at risk for the development of cardiovascular disease and diabetes mellitus type 2, the development of new kits for the measurement of gp91phox and HMGB1), School of Medicine, Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy
- 2006 Scholarship (topic: respiratory pharmacology), Scientific Association for the Study of Respiratory Diseases (AIMAR), Borgomanero, Italy
- 2002 Scholarship (topic: Clinical Science and Pharmaco-Toxicology), School of Veterinary Medicine, University of Naples Federico II, Naples, Italy.
- 2002 Scholarship (topic: veterinary pharmacology and toxicology), School of Veterinary Medicine, University of Teramo, Italy

- **SUPERVISION OF GRADUATE STUDENTS AND POSTDOCTORAL FELLOWS**

- 2014 – today 4 graduate student, School of Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy
- 2016 – today 2 PhD student, School of Medicine, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome, Italy

- **TEACHING ACTIVITIES**

- 2020 – today Professor of Respiratory disease (06/D1 MED/10) at the UniCamillus International Medical University in Rome, Italy.
- 2019 – today Professor of Respiratory disease (06/D1 MED/10) at University of Parma, Italy.
- 2019 – today Adjunct professor at the Master of Pharmacy, Degree Course in Pharmacy, University of Rome “Tor Vergata”, Rome, Italy.
- 2017 – today Adjunct professor at the School of Pharmacy and Nutraceutical, Department of Health Sciences, University of Catanzaro "Magna Graecia," Catanzaro, Italy.
- 2016 – today Adjunct professor at the Postgraduate School of Respiratory Medicine (topic: respiratory pharmacology), Department of Experimental Medicine, School of Medicine, University of Rome “Tor Vergata”, Rome, Italy
- 2013 – today Teaching activity (topic: anaesthesia, analgesia and euthanasia in laboratory animals), Centro Interdipartimentale Stazione per la Tecnologia Animale (STA), University of Rome “Tor Vergata”, Rome, Italy
- 2010 Teaching activity (topic: respiratory pharmacology), Workshop in Respiratory Diseases Improving Medical Expertise, University of Rome “Tor Vergata”, Rome, Italy
- 2005 – 2009 Tutoring activity (topic: Bachelor of Science degree in Veterinary Medicine), CESD S.r.L., Teramo, Italy

- **ORGANISATION OF SCIENTIFIC MEETINGS**

- 2016 Invited Faculty of “Contribution to the advancement of knowledge of obstructive bronchial diseases”, 60 participants, Scientific Congress, Rome, Italy
- 2016 Invited Faculty of “XVII Italian Congress of Pneumology”, >500 participants, Scientific Congress, Milan, Italy
- 2015 Invited Faculty of “Chest National Congress 2015” (Chest delegation Italy), >100 participants, Scientific Congress, Rome, Italy
- 2007 Congress Chair and Organizing Committee of “Abyssinian people in Abruzzo: new perspectives for international cooperation”, 50 participants, Scientific Congress, Rome, Italy
- 2006 Congress Chair and Organizing Committee of "Our pastors, pastoral reality of the mountain Teramana in the area of the National Park of Gran Sasso and Monti della Laga", 50 participants, Scientific Congress, 50 participants, Rome, Italy
- 2005 Congress Chair and Organizing Committee of "The relationship between different professionals and development of developing countries", 50 participants, Scientific Congress, 50 participants, Rome, Italy

- **COMMISSIONS OF TRUST**

- 2015 – today Scientific Advisory Board (respiratory clinical pharmacology and veterinary clinical pharmacology), School of Pharmacology, University of Rome “Tor Vergata”, Rome, Italy
- 2018 French Third RHU call (University Hospital Research) evaluation committee: external reviewer for the Agence nationale de la recherche (ANR, France).

- **EDITORIAL COMMITMENTS**

- 2016 - today Special Content Editor (Associate Editor) at Pulmonary Pharmacology and Therapeutics, Elsevier.
- 2017 – today Faculty member at F1000 Prime: publisher of services for life scientists and clinical researchers.

- **MEMBERSHIPS OF SCIENTIFIC SOCIETIES**

- 2015 – today ERS (European Respiratory Society)  
 2015 – 2016 ACCP/CHEST (American College of Chest Physicians)  
 2004 – 2006 SIVtro – VSF  
 2002 – 2003 S.I.S.Vet. (Italian Society of Veterinary Sciences)

- **MAJOR COLLABORATIONS**

- Prof. Clive Page and dr. Domenico Spina (topic: respiratory pharmacology), Sackler Institute of Pulmonary Pharmacology, Pharmaceutical Science Research Division, King's College London, London, UK  
 Prof. Maria Gabriella Matera (topic: respiratory pharmacology), Department of Experimental Medicine, Second University of Naples, Naples, Italy  
 Prof. Mario Cazzola, Prof. Paola Rogliani and Prof. Davide Lauro (topic: respiratory pharmacology), School of Medicine, Department of Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy  
 Prof. Luigi Bonizzi (topic: respiratory pharmacology), Department of Veterinary Medicine, School of Veterinary Medicine, University of Milan, Italy  
 Dr. Paola Roncada (topic: respiratory pharmacology), Istituto Sperimentale Italiano L. Spallanzani, Milan, Italy  
 Prof. Andrea Urbani (topic: respiratory pharmacology), School of Medicine, Catholic University of the Sacred Heart, Rome, Italy  
 Dr. Glenn Jacobson (topic: respiratory pharmacology), School of Medicine, University of Tasmania, Australia

**Selected invited presentations**

- Sept. 2019 European Respiratory Society (ERS) International Congress, Madrid, Spain  
 Sept. 2018 European Respiratory Society (ERS) International Congress, Paris, France  
 Sept. 2017 European Respiratory Society (ERS) International Congress, Rome, Italy  
 May 2017 American Thoracic Society (ATS) International Congress, San Diego, California, USA  
 Sept. 2016 European Respiratory Society (ERS) International Congress, London, UK  
 Oct. 2016 XVII Italian Congress of Pneumology, Milan, Italy  
 March 2015 Chest Congress (delegation Italy), Rome, Italy  
 Sept. 2015 European Respiratory Society (ERS) International Congress, Amsterdam, Netherlands  
 Sept. 2014 European Respiratory Society (ERS) International Congress, Munich, Germany  
 May 2014 American Thoracic Society (ATS) International Congress, San Diego, California, USA  
 Feb. 2011 Seminar at Sackler Institute of Pulmonary Pharmacology, King's College London, UK  
 May 2010 American Thoracic Society (ATS) International Congress, New Orleans, Louisiana, USA  
 Sept. 2009 European Respiratory Society (ERS) International Congress, Vienna, Austria

**Granted patents and software**

1. US International Patent – US9700558B2, 2017. Title: Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist. Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenyl)mino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquino lin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist. Inventors: Michael J.A. Walker, Mario Cazzola, **Luigino Calzetta**.
2. US International Patent -US9717732B2, 2017. Title: Drug combination. Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenyl)mino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquino lin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a  $\beta$ 2-adrenergic receptor agonist. Inventors: Michael J.A. Walker, Mario Cazzola, **Luigino Calzetta**.
3. EU International Patent - EP2968312B1, 2018. Title: Drug combination. Summary: The present invention relates to a new combination of drugs which has surprising therapeutic efficacy in the treatment of respiratory and inflammatory disorders. It is a surprising finding of the present invention that RPL554 is capable of potentiating the activity of  $\beta$ 2-adrenergic receptor agonists. RPL554 and  $\beta$ 2-adrenergic receptor agonists therefore interact synergistically in combination to provide an improved therapeutic effect. Inventors: Michael J.A. Walker, Mario Cazzola, **Luigino Calzetta**.

4. EU International Patent - EP2968313B1, 2018. Title: Drug combination. Summary: The present invention relates to a new combination of drugs which has surprising therapeutic efficacy in the treatment of respiratory and inflammatory disorders. It is a surprising finding of the present invention that RPL554 is capable of potentiating the activity of muscarinic receptor antagonists. RPL554 and muscarinic receptor antagonists therefore interact synergistically in combination to provide an improved therapeutic effect. Inventors: Michael J.A. Walker, Mario Cazzola, **Luigino Calzetta**
5. EU International Patent - PCT/IT2010/000361, August 9, 2010. Title: Portable device for monitoring and reporting of medical information for the evidence-based management of patients with chronic respiratory disease. Inventors: **Calzetta Luigino**, Saltini Cesare, Sacco Boschetti Paolo
6. COPDCoRi: “An application for estimating and predicting the risk of coronary artery disease (CAD) in patients with chronic obstructive pulmonary disease (COPD)”. Rogliani P, Romeo F, Matera MG, **Calzetta L**. Deposito SIAE n. 2013001671 – 2013.
7. IDEASS: an Improved clinically Detectable Equine Asthma Scoring System: un algoritmo implementato applicabile a diversi software. IDEASS is an algorithm applicable to software (android, iOS, windows, OSX) that permits to clinically quantify the level of equine asthma severity via an 8-point scale. **Calzetta L**, Rogliani P, Pistocchini E. Deposito SIAE n. 2017002958 – 2017.

### Prizes, awards and academy memberships

- March 2015    CHEST “Matteo Sofia” Young Researcher Award
- Oct. 2013    Honorary Researcher at Sackler Institute of Pulmonary Pharmacology, King’s College London, London (UK)
- June 2002    Prize for veterinary medicine thesis of high scientific impact

### Bibliometric profile, SCOPUS (19/12/2020)

## Calzetta, Luigino

[University of Parma, Parma, Italy](#) [Show all author info](#)

[SC](#) 26633652400 [ORCID](#) <https://orcid.org/0000-0003-0456-069X>

[Edit profile](#) [Set alert](#) [Save to list](#) [Potential aut](#)  
[Export to SciVal](#)


#### Metrics overview

209  
Documents by author

3490  
Citations by 1976 documents

32  
h-index: [View h-graph](#)

#### Document & citation trends



[Analyze author output](#) [Citation overview](#)

**Publications**

- [1] P. Rogliani, M. Sforza, **L. Calzetta**, The impact of comorbidities on severe asthma, *Current opinion in pulmonary medicine* 26(1) (2020) 47-55.
- [2] P. Rogliani, B.L. Ritondo, B. Zerillo, M. Cazzola, M.G. Matera, **L. Calzetta**, Adding a Second Bronchodilator in COPD: A Meta-Analysis on the Risk of Specific Cardiovascular Serious Adverse Events of Tiotropium/Olodaterol Fixed-Dose Combination, *Copd* 17(2) (2020) 215-223.
- [3] P. Rogliani, B.L. Ritondo, E. Puxeddu, G. Pane, M. Cazzola, **L. Calzetta**, Experimental Glucocorticoid Receptor Agonists for the Treatment of Asthma: A Systematic Review, *Journal of experimental pharmacology* 12 (2020) 233-254.
- [4] P. Rogliani, B.L. Ritondo, J. Ora, M. Cazzola, **L. Calzetta**, SMART and as-needed therapies in mild-to-severe asthma: a network meta-analysis, *The European respiratory journal* 56(3) (2020).
- [5] P. Rogliani, B.L. Ritondo, R. Laitano, A. Chetta, **L. Calzetta**, Advances in understanding of mechanisms related to increased cardiovascular risk in COPD, *Expert review of respiratory medicine* (2020) 1-12.
- [6] P. Rogliani, B.L. Ritondo, M. Gabriele, M. Cazzola, **L. Calzetta**, Optimizing de-escalation of inhaled corticosteroids in COPD: a systematic review of real-world findings, *Expert review of clinical pharmacology* 13(9) (2020) 977-990.
- [7] P. Rogliani, M.G. Matera, F. Facciolo, C. Page, M. Cazzola, **L. Calzetta**, Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo, *British journal of pharmacology* 177(5) (2020) 1150-1163.
- [8] P. Rogliani, D. Lauro, N. Di Daniele, A. Chetta, **L. Calzetta**, Reduced risk of COVID-19 hospitalization in asthmatic and COPD patients: a benefit of inhaled corticosteroids?, *Expert review of respiratory medicine* (2020) 1-8.
- [9] P. Rogliani, **L. Calzetta**, M.G. Matera, R. Laitano, B.L. Ritondo, N.A. Hanania, M. Cazzola, Severe Asthma and Biological Therapy: When, Which, and for Whom, *Pulmonary therapy* 6(1) (2020) 47-66.
- [10] P. Rogliani, **L. Calzetta**, A. Coppola, E. Puxeddu, G. Sergiacomi, D. D'Amato, A. Orlicchio, Are there pulmonary sequelae in patients recovering from COVID-19?, *Respiratory research* 21(1) (2020) 286.
- [11] B.L. Ritondo, E. Puxeddu, **L. Calzetta**, M. Cazzola, P. Rogliani, Efficacy and safety of triple combination therapy for treating chronic obstructive pulmonary disease: an expert review, *Expert opinion on pharmacotherapy* (2020) 1-10.
- [12] J. Ora, A. Coppola, M. Cazzola, **L. Calzetta**, P. Rogliani, Long-Acting Muscarinic Antagonists Under Investigational to Treat Chronic Obstructive Pulmonary Disease, *Journal of experimental pharmacology* 12 (2020) 559-574.
- [13] J. Ora, **L. Calzetta**, M.G. Matera, M. Cazzola, P. Rogliani, Advances with glucocorticoids in the treatment of asthma: state of the art, *Expert opinion on pharmacotherapy* 21(18) (2020) 2305-2316.
- [14] M.G. Matera, P. Rogliani, **L. Calzetta**, M. Cazzola, TSLP Inhibitors for Asthma: Current Status and Future Prospects, *Drugs* 80(5) (2020) 449-458.
- [15] M.G. Matera, P. Rogliani, **L. Calzetta**, M. Cazzola, Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review, *Respiratory medicine* 171 (2020) 106114.
- [16] M.G. Matera, C.P. Page, **L. Calzetta**, P. Rogliani, M. Cazzola, Pharmacology and Therapeutics of Bronchodilators Revisited, *Pharmacological reviews* 72(1) (2020) 218-252.
- [17] G. Liccardi, **L. Calzetta**, M. Milanese, M.B. Bilò, M.V. Liccardi, M.G. Matera, P. Rogliani, Anxiety and depression in adolescents with asthma and in their parents. Is an increased basal cholinergic tone a possible further reason to explain the negative impact on asthma control?, *Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace* 90(1) (2020).
- [18] G. Liccardi, **L. Calzetta**, M. Milanese, M.B. Bilò, M.V. Liccardi, M.G. Matera, I. Baiardini, P. Rogliani, Anxiety/depression and impaired asthma control in adolescents. Is an increased basal cholinergic tone a possible link ?, *European annals of allergy and clinical immunology* 52(4) (2020) 190-192.
- [19] G. Liccardi, **L. Calzetta**, M.B. Bilò, I. Brusca, L. Cecchi, M.T. Costantino, M. Da Re, F. Buzzulini, M. Giani, C. Lombardi, G. Meneguzzi, A. Meriggi, M. Milanese, R. Onida, V. Patella, P. Pignatti, O. Quercia, E. Ridolo, G. Sabatino, C. Sacerdoti, E. Savi, E. Scala, G. Steinhilber, D. Villalta, G. Passalacqua, P. Rogliani, A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study, *The journal of allergy and clinical immunology. In practice* 8(7) (2020) 2399-2401.
- [20] G. Liccardi, **L. Calzetta**, A. Berra, R. Caiazzo, F. Califano, A. Ciccarelli, M. Cutajar, M. D'Amato, F. De Bartolomeis, I. Dello Iacono, D. Gargano, M. Lo Schiavo, F. Madonna, M. Maniscalco, M. Milanese, C. Montera, R. Narducci, G. Papa, A. Pedicini, G. Sabatino, C. Sacerdoti, A. Savoia, A. Stanziola, M.B. Bilò, P. Rogliani, Unmet needs and relationship between general practitioners (GPs) and allergists living in Campania region (southern Italy), *European annals of allergy and clinical immunology* 52(5) (2020) 230-234.
- [21] R. Crupi, E. Palma, R. Siracusa, R. Fusco, E. Gugliandolo, M. Cordaro, D. Impellizzeri, C. De Caro, **L. Calzetta**, S. Cuzzocrea, R. Di Paola, Protective Effect of Hydroxytyrosol Against Oxidative Stress Induced by the Ochratoxin in Kidney Cells: in vitro and in vivo Study, *Frontiers in veterinary science* 7 (2020) 136.
- [22] M. Cazzola, P. Rogliani, **L. Calzetta**, M.G. Matera, Pharmacogenomic Response of Inhaled Corticosteroids for the Treatment of Asthma: Considerations for Therapy, *Pharmacogenomics and personalized medicine* 13 (2020) 261-271.
- [23] M. Cazzola, C. Page, P. Rogliani, **L. Calzetta**, M.G. Matera, Multifaceted Beneficial Effects of Erdosteine: More than a Mucolytic Agent, *Drugs* 80(17) (2020) 1799-1809.
- [24] **L. Calzetta**, B.L. Ritondo, M.G. Matera, G. Pezzuto, M. Cazzola, P. Rogliani, Investigational treatments in phase I and II clinical trials: a systematic review in chronic obstructive pulmonary disease (COPD), *Expert opinion on investigational drugs* 29(7) (2020) 723-738.
- [25] **L. Calzetta**, B.L. Ritondo, M.G. Matera, F. Facciolo, P. Rogliani, Targeting IL-5 pathway against airway hyperresponsiveness: A comparison between benralizumab and mepolizumab, *British journal of pharmacology* 177(20) (2020) 4750-4765.

- [26] **L. Calzetta**, B.L. Ritondo, M.G. Matera, M. Cazzola, P. Rogliani, Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review, *Expert review of respiratory medicine* 14(6) (2020) 621-635.
- [27] **L. Calzetta**, B.L. Ritondo, P. de Marco, M. Cazzola, P. Rogliani, Evaluating triple ICS/LABA/LAMA therapies for COPD patients: a network meta-analysis of ETHOS, KRONOS, IMPACT, and TRILOGY studies, *Expert review of respiratory medicine* (2020) 1-10.
- [28] **L. Calzetta**, E. Pistocchini, B.L. Ritondo, P. Roncada, E. Palma, D. di Cave, M. Mattei, D. Britti, Immunoprophylaxis pharmacotherapy against canine leishmaniasis: A systematic review and meta-analysis on the efficacy of vaccines approved in European Union, *Vaccine* 38(43) (2020) 6695-6703.
- [29] **L. Calzetta**, E. Pistocchini, A. Leo, P. Roncada, B.L. Ritondo, E. Palma, D. di Cave, D. Britti, Anthelmintic medicinal plants in veterinary ethnopharmacology: A network meta-analysis following the PRISMA-P and PROSPERO recommendations, *Heliyon* 6(2) (2020) e03256.
- [30] **L. Calzetta**, M.G. Matera, P. Rogliani, M. Cazzola, The role of triple therapy in the management of COPD, *Expert review of clinical pharmacology* 13(8) (2020) 865-874.
- [31] **L. Calzetta**, M.G. Matera, M.F. Goldstein, W.R. Fairweather, W.W. Howard, M. Cazzola, P. Rogliani, A long-term clinical trial on the efficacy and safety profile of doxofylline in Asthma: The LESDA study, *Pulmonary pharmacology & therapeutics* 60 (2020) 101883.
- [32] **L. Calzetta**, M.G. Matera, A. Coppola, P. Rogliani, Prospects for severe asthma treatment, *Current opinion in pharmacology* 56 (2020) 52-60.
- [33] **L. Calzetta**, B. Ludovica Ritondo, P. de Marco, M. Cazzola, P. Rogliani, Reply to Han et al.: Impact on mortality of triple ICS/LABA/LAMA therapy in a population of COPD patients including also subjects with asthma-like profile, *Expert review of respiratory medicine* (2020).
- [34] **L. Calzetta**, R. Crupi, P. Roncada, E. Pistocchini, D. di Cave, I. Rossi, G. Cito, G.A. Jacobson, D. Britti, Clinical efficacy of bronchodilators in equine asthma: Looking for minimal important difference, *Equine veterinary journal* 52(2) (2020) 305-313.
- [35] D. Villalta, M. Milanese, M. Da Re, G. Sabatino, M. Sforza, **L. Calzetta**, G. Liccardi, Frequency of allergic sensitization to Can f 5 in North East Italy. An analysis of 1403 ISACs 112 (Component Resolved Diagnosis) collected retrospectively, *European annals of allergy and clinical immunology* 51(4) (2019) 186-189.
- [36] P. Rogliani, M.G. Matera, B.L. Ritondo, I. De Guido, E. Puxeddu, M. Cazzola, **L. Calzetta**, Efficacy and cardiovascular safety profile of dual bronchodilation therapy in chronic obstructive pulmonary disease: A bidimensional comparative analysis across fixed-dose combinations, *Pulmonary pharmacology & therapeutics* 59 (2019) 101841.
- [37] P. Rogliani, M.G. Matera, C. Page, E. Puxeddu, M. Cazzola, **L. Calzetta**, Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine, *Respiratory research* 20(1) (2019) 104.
- [38] P. Rogliani, M.G. Matera, **L. Calzetta**, N.A. Hanania, C. Page, I. Rossi, A. Andreadi, A. Galli, A. Coppola, M. Cazzola, D. Lauro, Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients, *Respiratory medicine* 154 (2019) 86-92.
- [39] P. Rogliani, M. Cazzola, **L. Calzetta**, Cardiovascular Disease in Chronic Respiratory Disorders and Beyond, *Journal of the American College of Cardiology* 73(17) (2019) 2178-2180.
- [40] P. Rogliani, **L. Calzetta**, J. Ora, M. Cazzola, M.G. Matera, Efficacy and safety profile of doxofylline compared to theophylline in asthma: a meta-analysis, *Multidisciplinary respiratory medicine* 14 (2019) 25.
- [41] P. Rogliani, **L. Calzetta**, M.G. Matera, N. di Daniele, A. Girolami, M. Cazzola, J. Ora, Inhaled therapies and cardiovascular risk in patients with chronic obstructive pulmonary disease, *Expert opinion on pharmacotherapy* 20(6) (2019) 737-750.
- [42] S. Principe, A. Benfante, **L. Calzetta**, P. Rogliani, N. Scichilone, Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics, *The World Allergy Organization journal* 12(11) (2019) 100081.
- [43] M.G. Matera, B. Rinaldi, **L. Calzetta**, P. Rogliani, M. Cazzola, Pharmacokinetics and pharmacodynamics of inhaled corticosteroids for asthma treatment, *Pulmonary pharmacology & therapeutics* 58 (2019) 101828.
- [44] M.G. Matera, **L. Calzetta**, P. Rogliani, M. Cazzola, Monoclonal antibodies for severe asthma: Pharmacokinetic profiles, *Respiratory medicine* 153 (2019) 3-13.
- [45] G. Liccardi, **L. Calzetta**, M. Milanese, G. Passalacqua, P. Rogliani, Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it, *The Journal of allergy and clinical immunology* 143(4) (2019) 1657-1658.
- [46] G. Liccardi, **L. Calzetta**, M. Milanese, M.B. Bilò, P. Rogliani, Sensitization to Cat: Why Not Use Molecular Diagnostics instead of the Nasal Challenge in Clinical Practice?, *International archives of allergy and immunology* 180(2) (2019) 142-143.
- [47] G. Liccardi, **L. Calzetta**, M. Milanese, M.B. Bilò, P. Rogliani, Why Are Allergens Not Detected in the Bronchoalveolar Lavage Fluid of Patients Undergoing Fiberoptic Bronchoscopy? Possible Explanations, *Journal of investigational allergology & clinical immunology* 29(6) (2019) 472-473.
- [48] G. Liccardi, **L. Calzetta**, M. Milanese, G. Apicella, P. Rogliani, The possible concomitant use of aeroallergen and food panels for skin prick testing might enhance the risk of generalized allergic reactions in children, *The Turkish journal of pediatrics* 61(5) (2019) 815-816.
- [49] G. Liccardi, **L. Calzetta**, G. Apicella, G. Baldi, A. Berra, F. Califano, A. Ciccarelli, M. Cutajar, M. D'Amato, G. De Crescenzo, E. Di Maro, D. Gargano, D. Giannattasio, G. Inciso, M. Lo Schiavo, F. Madonna, M. Maniscalco, C. Montera, G. Papa, A. Pedicini, R. Pio, A. Salzillo, A. Stanzola, P. Rogliani, A. Musarra, Allergy in adolescent population (14-18 years) living in Campania region (Southern Italy). A multicenter study, *European annals of allergy and clinical immunology* 51(1) (2019).
- [50] M. Cazzola, P. Rogliani, **L. Calzetta**, M.G. Matera, Bronchodilators in subjects with asthma-related comorbidities, *Respiratory medicine* 151 (2019) 43-48.
- [51] M. Cazzola, **L. Calzetta**, P. Rogliani, M.G. Matera, Ensifentrine (RPL554): an investigational PDE3/4 inhibitor for the treatment of COPD, *Expert opinion on investigational drugs* 28(10) (2019) 827-833.

- [52] M. Cazzola, **L. Calzetta**, P. Rogliani, M.G. Matera, Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting  $\beta$ -Agonists in COPD: Accumulating Evidence from Network Meta-Analyses, *Pulmonary therapy* 5(2) (2019) 117-126.
- [53] M. Cazzola, **L. Calzetta**, C. Page, P. Rogliani, M.G. Matera, Thiol-Based Drugs in Pulmonary Medicine: Much More than Mucolytics, *Trends in pharmacological sciences* 40(7) (2019) 452-463.
- [54] **L. Calzetta**, P. Rogliani, C. Page, B. Rinaldi, M. Cazzola, M.G. Matera, Pharmacological characterization of the interaction between tiotropium bromide and olodaterol on human bronchi and small airways, *Pulmonary pharmacology & therapeutics* 56 (2019) 39-50.
- [55] **L. Calzetta**, E. Pistocchini, B.L. Ritondo, P. Roncada, G. Cito, D. Britti, M.G. Matera, Isolated airways in equine respiratory pharmacology: They never lie, *Pulmonary pharmacology & therapeutics* 59 (2019) 101849.
- [56] **L. Calzetta**, M.G. Matera, P. Rogliani, Monoclonal antibodies in severe asthma: is it worth it?, *Expert opinion on drug metabolism & toxicology* 15(6) (2019) 517-520.
- [57] **L. Calzetta**, M.G. Matera, M. Cazzola, P. Rogliani, Optimizing the Development Strategy of Combination Therapy in Respiratory Medicine: From Isolated Airways to Patients, *Advances in therapy* 36(12) (2019) 3291-3298.
- [58] **L. Calzetta**, F. Di Marco, F. Blasi, M. Cazzola, S. Centanni, C. Micheletto, A. Rossi, P. Rogliani, Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis, *Pulmonary pharmacology & therapeutics* 59 (2019) 101855.
- [59] **L. Calzetta**, M. Cazzola, M.G. Matera, P. Rogliani, Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD, *Chest* 155(4) (2019) 758-770.
- [60] **L. Calzetta**, M. Cazzola, M.G. Matera, P. Rogliani, Response, *Chest* 155(5) (2019) 1079-1080.
- [61] J.K. Shute, E. Puxeddu, **L. Calzetta**, Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD, *Current opinion in pharmacology* 40 (2018) 39-45.
- [62] J.K. Shute, **L. Calzetta**, V. Cardaci, S. di Toro, C.P. Page, M. Cazzola, Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study, *Pulmonary pharmacology & therapeutics* 48 (2018) 88-96.
- [63] P. Rogliani, J. Ora, E. Puxeddu, **L. Calzetta**, F. Cavalli, M.G. Matera, M. Cazzola, Effect of adding roflumilast or ciclesonide to glycopyrronium on lung volumes and exercise tolerance in patients with severe COPD: A pilot study, *Pulmonary pharmacology & therapeutics* 49 (2018) 20-26.
- [64] P. Rogliani, J. Ora, M.G. Matera, M. Cazzola, **L. Calzetta**, The safety of dual bronchodilation on cardiovascular serious adverse events in COPD, *Expert opinion on drug safety* 17(6) (2018) 589-596.
- [65] P. Rogliani, M.G. Matera, E. Puxeddu, M. Mantero, F. Blasi, M. Cazzola, **L. Calzetta**, Emerging biological therapies for treating chronic obstructive pulmonary disease: A pairwise and network meta-analysis, *Pulmonary pharmacology & therapeutics* 50 (2018) 28-37.
- [66] P. Rogliani, **L. Calzetta**, M. Cazzola, Is ICS-LAMA an alternative option to treat patients with COPD?, *The Lancet. Respiratory medicine* 6(5) (2018) 316-317.
- [67] P. Rogliani, **L. Calzetta**, F. Braido, M. Cazzola, E. Clini, G. Pelaia, A. Rossi, N. Scichilone, F. Di Marco, LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review, *International journal of chronic obstructive pulmonary disease* 13 (2018) 3115-3130.
- [68] M.G. Matera, P. Rogliani, **L. Calzetta**, M. Cazzola, Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma, *Expert opinion on drug metabolism & toxicology* 14(2) (2018) 239-245.
- [69] M.G. Matera, **L. Calzetta**, E. Puxeddu, P. Rogliani, M. Cazzola, A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD, *Expert opinion on drug safety* 17(5) (2018) 509-517.
- [70] M.G. Matera, **L. Calzetta**, G. Gritti, L. Gallo, B. Perfetto, G. Donnarumma, M. Cazzola, P. Rogliani, M. Donniacuo, B. Rinaldi, Role of statins and mevalonate pathway on impaired HDAC2 activity induced by oxidative stress in human airway epithelial cells, *European journal of pharmacology* 832 (2018) 114-119.
- [71] G. Liccardi, **L. Calzetta**, A. Salzillo, A. Piccolo, G. Apicella, P. Rogliani, Anxiety and asthma in youth. Is a stress-induced increased cholinergic tone the possible link?, *Pediatric pulmonology* 53(2) (2018) 128-129.
- [72] G. Liccardi, **L. Calzetta**, A. Salzillo, G. Apicella, A. Piccolo, E. Di Maro, P. Rogliani, Dog allergy: can a prevalent or exclusive sensitization to Can f 5 be considered a lucky or negative event in real life?, *European annals of allergy and clinical immunology* 50(6) (2018) 283-285.
- [73] G. Liccardi, **L. Calzetta**, M. Milanese, M. Scaglione, P. Rogliani, Occupational exposure to furry animals and asthma: The complex interconnection between work and everyday life, *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 121(4) (2018) 512-513.
- [74] G. Liccardi, **L. Calzetta**, M. Milanese, A. Salzillo, F. Manzi, M. Ferrari, P. Rogliani, Psychological Stress, Lung Function and Exacerbation Risk in COPD: Is an Increase of Cholinergic Tone a Possible Link?, *Copd* 15(3) (2018) 310-311.
- [75] G. Liccardi, **L. Calzetta**, M. Milanese, A. Salzillo, G. Apicella, M.G. Matera, P. Rogliani, Anxiety and asthma in inner-city black adolescents: What could be the underestimated, possible connection?, *The journal of allergy and clinical immunology. In practice* 6(3) (2018) 1093-1094.
- [76] G. Liccardi, **L. Calzetta**, M. Milanese, M. Maniscalco, A. Salzillo, P. Rogliani, Indoor environmental interventions for furry pet allergens: How to decrease the degree of passive transport, *The journal of allergy and clinical immunology. In practice* 6(5) (2018) 1808-1809.
- [77] G. Liccardi, **L. Calzetta**, M. Milanese, C. Lombardi, E. Savi, G. Passalacqua, P. Rogliani, Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?, *Human vaccines & immunotherapeutics* 14(6) (2018) 1438-1441.

- [78] G. Liccardi, **L. Calzetta**, G. Baldi, A. Berra, L. Billeri, M. Caminati, P. Capano, E. Carpentieri, A. Ciccarelli, M.A. Crivellaro, M. Cutajar, M. D'Amato, I. Folletti, F. Gani, D. Gargano, D. Giannattasio, M. Giovannini, C. Lombardi, M.L. Schiavo, F. Madonna, M. Maniscalco, A. Meriggi, C. Micucci, M. Milanese, C. Montera, G. Paolucci, R. Parente, A. Pedicini, R. Pio, F. Puggioni, M. Russo, A. Salzillo, P. Scavalli, N. Scichilone, B. Sposato, A. Stanziola, G. Steinhilber, A. Vatrella, P. Rogliani, G. Passalacqua, Allergic sensitization to common pets (cats/dogs) according to different possible modalities of exposure: an Italian Multicenter Study, *Clinical and molecular allergy : CMA* 16 (2018) 3.
- [79] G.A. Jacobson, S. Raidal, M. Hostrup, **L. Calzetta**, R. Wood-Baker, M.O. Farber, C.P. Page, E.H. Walters, Long-Acting  $\beta$ 2-Agonists in Asthma: Enantioselective Safety Studies are Needed, *Drug safety* 41(5) (2018) 441-449.
- [80] M. Cazzola, P. Rogliani, **L. Calzetta**, M.G. Matera, Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis, *The European respiratory journal* 52(6) (2018).
- [81] M. Cazzola, C. Page, **L. Calzetta**, M.G. Matera, Enfisentrine (RPL554): an inhaled 'bifunctional' dual PDE3/4 inhibitor for the treatment of asthma and chronic obstructive pulmonary disease, *Pharmaceutical patent analyst* 7(6) (2018) 249-257.
- [82] M. Cazzola, M.G. Matera, P. Rogliani, **L. Calzetta**, Senolytic drugs in respiratory medicine: is it an appropriate therapeutic approach?, *Expert opinion on investigational drugs* 27(7) (2018) 573-581.
- [83] M. Cazzola, **L. Calzetta**, P. Rogliani, C. Page, M.G. Matera, Impact of doxofylline in COPD: A pairwise meta-analysis, *Pulmonary pharmacology & therapeutics* 51 (2018) 1-9.
- [84] M. Cazzola, **L. Calzetta**, C. Page, P. Rogliani, M.G. Matera, Impact of erdosteine on chronic bronchitis and COPD: A meta-analysis, *Pulmonary pharmacology & therapeutics* 48 (2018) 185-194.
- [85] M. Cazzola, **L. Calzetta**, M.G. Matera, N.A. Hanania, P. Rogliani, How does race/ethnicity influence pharmacological response to asthma therapies?, *Expert opinion on drug metabolism & toxicology* 14(4) (2018) 435-446.
- [86] M. Cazzola, **L. Calzetta**, P.J. Barnes, G.J. Criner, F.J. Martinez, A. Papi, M. Gabriella Matera, Efficacy and safety profile of xanthines in COPD: a network meta-analysis, *European respiratory review : an official journal of the European Respiratory Society* 27(148) (2018).
- [87] **L. Calzetta**, P. Roncada, C. Piras, A. Soggiu, G. Liccardi, M. Mattei, E. Pistocchini, Geographical characteristics influencing the risk of poisoning in pet dogs: Results of a large population-based epidemiological study in Italy, *Veterinary journal (London, England : 1997)* 235 (2018) 63-69.
- [88] **L. Calzetta**, P. Rogliani, E. Pistocchini, M. Mattei, G. Cito, P. Alfonsi, C. Page, M.G. Matera, Effect of lipopolysaccharide on the responsiveness of equine bronchial tissue, *Pulmonary pharmacology & therapeutics* 49 (2018) 88-94.
- [89] **L. Calzetta**, P. Rogliani, E. Pistocchini, M. Mattei, G. Cito, P. Alfonsi, C. Page, M.G. Matera, Combining long-acting bronchodilators with different mechanisms of action: A pharmacological approach to optimize bronchodilation of equine airways, *Journal of veterinary pharmacology and therapeutics* 41(4) (2018) 546-554.
- [90] **L. Calzetta**, P. Rogliani, C. Page, P. Roncada, E. Pistocchini, A. Soggiu, C. Piras, A. Urbani, M.G. Matera, Clinical effect of corticosteroids in asthma-affected horses: A quantitative synthesis, *Equine veterinary journal* 50(5) (2018) 594-601.
- [91] **L. Calzetta**, P. Rogliani, F. Facciolo, B. Rinaldi, M. Cazzola, M.G. Matera, N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation, *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie* 103 (2018) 1-8.
- [92] **L. Calzetta**, M.G. Matera, P. Rogliani, M. Cazzola, Dual LABA/LAMA bronchodilators in chronic obstructive pulmonary disease: why, when, and how, *Expert review of respiratory medicine* 12(4) (2018) 261-264.
- [93] **L. Calzetta**, M.G. Matera, P. Rogliani, M. Cazzola, Multifaceted activity of N-acetyl-L-cysteine in chronic obstructive pulmonary disease, *Expert review of respiratory medicine* 12(8) (2018) 693-708.
- [94] **L. Calzetta**, M.G. Matera, F. Facciolo, M. Cazzola, P. Rogliani, Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways, *Respiratory research* 19(1) (2018) 65.
- [95] **L. Calzetta**, M.G. Matera, M. Cazzola, Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy, *Current opinion in pharmacology* 40 (2018) 95-103.
- [96] **L. Calzetta**, N.A. Hanania, F.L. Dini, M.F. Goldstein, W.R. Fairweather, W.W. Howard, M. Cazzola, Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2), *Pulmonary pharmacology & therapeutics* 53 (2018) 20-26.
- [97] P. Rossi, M. Montuori, P. Bove, A. De Majo, E. Ricciardi, M. Mattei, R. Bernardini, **L. Calzetta**, P. Mauti, L. Intini, V. Quattrini, C. Chiaramonte, A. Mauriello, G. Vespasiani, Partial renal resection by LaparoNewPro: in vivo open and laparoscopic study in an animal model, *Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy* 26(6) (2017) 315-321.
- [98] P. Rogliani, M.G. Matera, J. Ora, M. Cazzola, **L. Calzetta**, The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis, *International journal of chronic obstructive pulmonary disease* 12 (2017) 3469-3485.
- [99] P. Rogliani, **L. Calzetta**, A. Coppola, F. Cavalli, J. Ora, E. Puxeddu, M.G. Matera, M. Cazzola, Optimizing drug delivery in COPD: The role of inhaler devices, *Respiratory medicine* 124 (2017) 6-14.
- [100] M.G. Matera, P. Rogliani, **L. Calzetta**, G.W. Canonica, M. Cazzola, Benralizumab for the treatment of asthma, *Drugs of today (Barcelona, Spain : 1998)* 53(12) (2017) 633-645.
- [101] M.G. Matera, B. Rinaldi, **L. Calzetta**, M. Cazzola, Assessing the viability of long-acting  $\beta$ (2)-agonists in paediatric asthma patients: a pharmacokinetic/pharmacodynamic perspective, *Expert opinion on drug metabolism & toxicology* 13(2) (2017) 129-136.
- [102] M.G. Matera, B. Rinaldi, **L. Calzetta**, M. Cazzola, Pharmacogenetic and pharmacogenomic considerations of asthma treatment, *Expert opinion on drug metabolism & toxicology* 13(11) (2017) 1159-1167.
- [103] M.G. Matera, **L. Calzetta**, B. Rinaldi, M. Cazzola, Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma, *Expert opinion on drug metabolism & toxicology* 13(9) (2017) 1007-1013.



- [104] G. Liccardi, M. Caminati, G. Senna, **L. Calzetta**, P. Rogliani, Anaphylaxis and intimate behaviour, *Current opinion in allergy and clinical immunology* 17(5) (2017) 350-355.
- [105] G. Liccardi, **L. Calzetta**, A. Salzillo, E. Puxeddu, P. Rogliani, Relationship between oxytocin/vasopressin and latex in obstetric surgery: how to recognize (and prevent) allergic reactions and differentiate them from side effects?, *The journal of allergy and clinical immunology. In practice* 5(3) (2017) 873.
- [106] G. Liccardi, **L. Calzetta**, A. Salzillo, A. Piccolo, G. Pane, P. Rogliani, Can a better patient phenotyping predict the efficacy of tiotropium in asthmatic adolescents?, *Expert opinion on pharmacotherapy* 18(8) (2017) 833-835.
- [107] G. Liccardi, **L. Calzetta**, A. Salzillo, L. Billeri, G. Lucà, P. Rogliani, Letter to the Editor: Can dog allergen immunotherapy reduce concomitant allergic sensitization to other furry animals? A preliminary experience, *European annals of allergy and clinical immunology* 49(2) (2017) 92-96.
- [108] G. Liccardi, **L. Calzetta**, A. Salzillo, G. Apicella, E. Di Maro, P. Rogliani, What Could the Role of Can f 5 Allergen Be in Dog-Sensitized Patients in "Real Life"?, *Journal of investigational allergology & clinical immunology* 27(6) (2017) 397-398.
- [109] G. Liccardi, **L. Calzetta**, A. Salzillo, G. Apicella, G. Croce, P. Rogliani, Can a better patients' phenotyping predict the efficacy of tiotropium in symptomatic asthma?, *Allergy and asthma proceedings* 38(3) (2017) 19-20.
- [110] G. Liccardi, **L. Calzetta**, A. Salzillo, G. Apicella, F. Cavalli, P. Rogliani, Is H1-antihistamine (desloratadine 5 mg, orodispersible tablet) premedication in NSAID-associated urticaria really safe and practicable in "real life"?, *The journal of allergy and clinical immunology. In practice* 5(2) (2017) 535.
- [111] G. Liccardi, **L. Calzetta**, A. Barrile, F.M. Giorgino, C. Sapio, P. Rogliani, Is the risk of developing atopic sensitization and bronchial asthma in animal laboratory workers preventable in well-defined susceptible individuals?, *Journal of occupational health* 59(3) (2017) 310-311.
- [112] M. Contoli, A.G. Corsico, P. Santus, F. Di Marco, F. Braido, P. Rogliani, **L. Calzetta**, N. Scichilone, Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine, *Copd* 14(6) (2017) 641-647.
- [113] M. Cazzola, P. Rogliani, **L. Calzetta**, D. Lauro, C. Page, M.G. Matera, Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus, *Trends in pharmacological sciences* 38(10) (2017) 940-951.
- [114] M. Cazzola, P. Rogliani, **L. Calzetta**, N.A. Hanania, M.G. Matera, Impact of Mucolytic Agents on COPD Exacerbations: A Pair-wise and Network Meta-analysis, *Copd* 14(5) (2017) 552-563.
- [115] M. Cazzola, **L. Calzetta**, P. Rogliani, M.G. Matera, Tiotropium formulations and safety: a network meta-analysis, *Therapeutic advances in drug safety* 8(1) (2017) 17-30.
- [116] M. Cazzola, **L. Calzetta**, P. Rogliani, M.G. Matera, The Challenges of Precision Medicine in COPD, *Molecular diagnosis & therapy* 21(4) (2017) 345-355.
- [117] M. Cazzola, **L. Calzetta**, B. Rinaldi, C. Page, G. Rosano, P. Rogliani, M.G. Matera, Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases, *Drugs* 77(7) (2017) 721-732.
- [118] M. Cazzola, **L. Calzetta**, F. Facciolo, P. Rogliani, M.G. Matera, Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation, *Respiratory research* 18(1) (2017) 26.
- [119] **L. Calzetta**, P. Roncada, D. di Cave, L. Bonizzi, A. Urbani, E. Pistocchini, P. Rogliani, M.G. Matera, Pharmacological treatments in asthma-affected horses: A pair-wise and network meta-analysis, *Equine veterinary journal* 49(6) (2017) 710-717.
- [120] **L. Calzetta**, P. Rogliani, J. Ora, E. Puxeddu, M. Cazzola, M.G. Matera, LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment, *European respiratory review : an official journal of the European Respiratory Society* 26(143) (2017).
- [121] **L. Calzetta**, P. Rogliani, M. Mattei, P. Alfonsi, G. Cito, E. Pistocchini, M. Cazzola, M.G. Matera, Pharmacological characterization of the interaction between tiotropium and olodaterol administered at 5:5 concentration-ratio in equine bronchi, *Copd* 14(5) (2017) 526-532.
- [122] **L. Calzetta**, P. Rogliani, F. Facciolo, E. Rendina, M. Cazzola, M.G. Matera, Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi, *European journal of pharmacology* 812 (2017) 147-154.
- [123] **L. Calzetta**, E. Puxeddu, P. Rogliani, Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine, *EBioMedicine* 19 (2017) 14-15.
- [124] **L. Calzetta**, J. Ora, F. Cavalli, P. Rogliani, D.E. O'Donnell, M. Cazzola, Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis, *Respiratory medicine* 129 (2017) 189-198.
- [125] **L. Calzetta**, M.G. Matera, F. Braido, M. Contoli, A. Corsico, F. Di Marco, P. Santus, N. Scichilone, M. Cazzola, P. Rogliani, Withdrawal of inhaled corticosteroids in COPD: A meta-analysis, *Pulmonary pharmacology & therapeutics* 45 (2017) 148-158.
- [126] A. Soggiu, C. Piras, V. Greco, P. Devoto, A. Urbani, **L. Calzetta**, M. Bortolato, P. Roncada, Exploring the neural mechanisms of finasteride: a proteomic analysis in the nucleus accumbens, *Psychoneuroendocrinology* 74 (2016) 387-396.
- [127] P. Rogliani, E. Puxeddu, C. Ciaprini, J. Ora, A. Onorato, G. Pezzuto, **L. Calzetta**, M. Cazzola, The Time Course of Pulmonary Function Tests in COPD Patients with Different Levels of Blood Eosinophils, *BioMed research international* 2016 (2016) 4547953.
- [128] P. Rogliani, **L. Calzetta**, M. Cazzola, M.G. Matera, Drug safety evaluation of roflumilast for the treatment of COPD: a meta-analysis, *Expert opinion on drug safety* 15(8) (2016) 1133-46.
- [129] P. Rogliani, **L. Calzetta**, F. Cavalli, M.G. Matera, M. Cazzola, Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis, *Pulmonary pharmacology & therapeutics* 40 (2016) 95-103.
- [130] P. Rogliani, **L. Calzetta**, B. Capuani, F. Facciolo, M. Cazzola, D. Lauro, M.G. Matera, Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness, *American journal of respiratory cell and molecular biology* 55(6) (2016) 804-814.
- [131] M.G. Matera, P. Rogliani, **L. Calzetta**, M. Cazzola, Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update, *Drug safety* 39(6) (2016) 501-8.

- [132] M.G. Matera, C. Page, P. Rogliani, **L. Calzetta**, M. Cazzola, Therapeutic Monoclonal Antibodies for the Treatment of Chronic Obstructive Pulmonary Disease, *Drugs* 76(13) (2016) 1257-1270.
- [133] M.G. Matera, **L. Calzetta**, M. Cazzola, Oxidation pathway and exacerbations in COPD: the role of NAC, *Expert review of respiratory medicine* 10(1) (2016) 89-97.
- [134] G. Liccardi, A. Salzillo, A. Piccolo, **L. Calzetta**, P. Rogliani, Dysfunction of small airways and prevalence, airway responsiveness and inflammation in asthma: much more than small particle size of pet animal allergens, *Upsala journal of medical sciences* 121(3) (2016) 196-7.
- [135] G. Liccardi, A. Salzillo, **L. Calzetta**, P. Pignatti, P. Rogliani, Can pet keeping be considered the only criterion of exposure to cat/dog allergens in the first year of life?, *Allergologia et immunopathologia* 44(4) (2016) 387-8.
- [136] G. Liccardi, A. Salzillo, **L. Calzetta**, A. Piccolo, P. Rogliani, How many systemic reactions to skin prick tests could be preventable in defined conditions?, *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 116(2) (2016) 174.
- [137] G. Liccardi, A. Salzillo, **L. Calzetta**, A. Piccolo, P. Rogliani, Chronic cat allergen exposure and low sensitization: Possible limitations in patient selection?, *The Journal of allergy and clinical immunology* 137(5) (2016) 1621-2.
- [138] G. Liccardi, A. Salzillo, **L. Calzetta**, A. Piccolo, P. Rogliani, Assessment of pet exposure by questionnaires in epidemiological studies (but also in clinical practice!): Why the questions should be simplified?, *The Journal of asthma : official journal of the Association for the Care of Asthma* 53(9) (2016) 879-81.
- [139] G. Liccardi, A. Salzillo, **L. Calzetta**, A. Piccolo, E. Puxeddu, P. Rogliani, Is Allergic Sensitization to Siberian Hamster Preventable in High-Risk Individuals Who Are Already Sensitized or Exposed to Furry Animals?, *Journal of investigational allergology & clinical immunology* 26(6) (2016) 403-405.
- [140] G. Liccardi, A. Salzillo, **L. Calzetta**, A. Piccolo, G. Menna, P. Rogliani, Can the presence of cat/dog at home be considered the only criterion of exposure to cat/dog allergens? A likely underestimated bias in clinical practice and in large epidemiological studies, *European annals of allergy and clinical immunology* 48(2) (2016) 61-4.
- [141] G. Liccardi, A. Salzillo, **L. Calzetta**, J. Ora, P. Rogliani, Dog allergen immunotherapy and allergy to furry animals, *Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology* 116(6) (2016) 590.
- [142] G. Liccardi, A. Salzillo, **L. Calzetta**, J. Ora, P. Rogliani, Gastroesophageal reflux and COPD exacerbations: Is cholinergic-mediated oesophago-bronchial reflex a possible link?, *Respirology (Carlton, Vic.)* 21(8) (2016) 1496-1497.
- [143] G. Liccardi, A. Salzillo, **L. Calzetta**, J. Ora, M. Cazzola, M.G. Matera, P. Rogliani, Can an increased cholinergic tone constitute a predictor of positive response to tiotropium in patients with moderate asthma?, *The journal of allergy and clinical immunology. In practice* 4(4) (2016) 791-3.
- [144] G. Liccardi, A. Salzillo, **L. Calzetta**, M. Cazzola, M.G. Matera, P. Rogliani, Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics, *Respiratory medicine* 117 (2016) 150-3.
- [145] G. Liccardi, **L. Calzetta**, C. Sapio, P. Rogliani, Occupational allergy to horse allergens: More than exposure to horses!, *International journal of occupational medicine and environmental health* 29(5) (2016) 721-3.
- [146] S. Lauretti, V. Cardaci, F. Barrese, **L. Calzetta**, Chronic obstructive pulmonary disease (COPD) and erectile dysfunction (ED): Results of the BRED observational study, *Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica* 88(3) (2016) 165-170.
- [147] M. Cazzola, J. Ora, A. Di Paolo, E. Puxeddu, **L. Calzetta**, P. Rogliani, Onset of action of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in patients with COPD, *Pulmonary pharmacology & therapeutics* 39 (2016) 48-53.
- [148] M. Cazzola, **L. Calzetta**, P. Rogliani, E. Puxeddu, F. Facciolo, M.G. Matera, Interaction between corticosteroids and muscarinic antagonists in human airways, *Pulmonary pharmacology & therapeutics* 36 (2016) 1-9.
- [149] M. Cazzola, **L. Calzetta**, P. Rogliani, M.G. Matera, The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease, *Expert opinion on drug discovery* 11(7) (2016) 733-44.
- [150] M. Cazzola, **L. Calzetta**, E. Puxeddu, J. Ora, F. Facciolo, P. Rogliani, M.G. Matera, Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells, *Respiratory research* 17(1) (2016) 70.
- [151] **L. Calzetta**, P. Rogliani, M.G. Matera, M. Cazzola, A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD, *Chest* 149(5) (2016) 1181-96.
- [152] **L. Calzetta**, B. Rinaldi, M. Cazzola, M.G. Matera, Pharmacodynamic and pharmacokinetic assessment of fluticasone furoate + vilanterol for the treatment of asthma, *Expert opinion on drug metabolism & toxicology* 12(7) (2016) 813-22.
- [153] **L. Calzetta**, A. Orlandi, C. Page, P. Rogliani, B. Rinaldi, G. Rosano, M. Cazzola, M.G. Matera, Brain natriuretic peptide: Much more than a biomarker, *International journal of cardiology* 221 (2016) 1031-8.
- [154] **L. Calzetta**, C. Ciapriani, E. Puxeddu, M. Cazzola, Olodaterol + tiotropium bromide for the treatment of COPD, *Expert review of respiratory medicine* 10(4) (2016) 379-386.
- [155] P. Rogliani, **L. Calzetta**, J. Ora, M.G. Matera, Canakinumab for the treatment of chronic obstructive pulmonary disease, *Pulmonary pharmacology & therapeutics* 31 (2015) 15-27.
- [156] P. Rogliani, **L. Calzetta**, J. Ora, R. Lipsi, A. Segreti, M.G. Matera, M. Cazzola, Pharmacological assessment of the onset of action of aclidinium and glycopyrronium versus tiotropium in COPD patients and human isolated bronchi, *European journal of pharmacology* 761 (2015) 383-90.
- [157] B. Rinaldi, M. Donniacuo, L. Sodano, G. Gritti, E. Martuscelli, A. Orlandi, C. Rafaniello, F. Rossi, **L. Calzetta**, A. Capuano, M.G. Matera, Effects of chronic treatment with the new ultra-long-acting  $\beta_2$ -adrenoceptor agonist indacaterol alone or in combination with the  $\beta_1$ -adrenoceptor blocker metoprolol on cardiac remodelling, *British journal of pharmacology* 172(14) (2015) 3627-37.

- [158] A. Orlandi, **L. Calzetta**, E. Doldo, C. Tarquini, M.G. Matera, D. Passeri, Brain natriuretic peptide modulates calcium homeostasis and epidermal growth factor receptor gene signalling in asthmatic airways smooth muscle cells, *Pulmonary pharmacology & therapeutics* 31 (2015) 51-4.
- [159] M. Cazzola, **L. Calzetta**, A. Segreti, F. Facciolo, P. Rogliani, M.G. Matera, Translational Study Searching for Synergy between Glycopyrronium and Indacaterol, *Copd* 12(2) (2015) 175-81.
- [160] M. Cazzola, **L. Calzetta**, C. Page, J. Jardim, A.G. Chuchalin, P. Rogliani, M.G. Matera, Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis, *European respiratory review : an official journal of the European Respiratory Society* 24(137) (2015) 451-61.
- [161] M. Cazzola, **L. Calzetta**, J. Ora, E. Puxeddu, P. Rogliani, M.G. Matera, Searching for the synergistic effect between acclidinium and formoterol: From bench to bedside, *Respiratory medicine* 109(10) (2015) 1305-11.
- [162] M. Cazzola, **L. Calzetta**, M.G. Matera, S. Muscoli, P. Rogliani, F. Romeo, Chronic obstructive pulmonary disease and coronary disease: COPDCoRi, a simple and effective algorithm for predicting the risk of coronary artery disease in COPD patients, *Respiratory medicine* 109(8) (2015) 1019-25.
- [163] M. Cazzola, **L. Calzetta**, M.G. Matera, Acclidinium/formoterol fixed-dose combination for the treatment of chronic obstructive pulmonary disease, *Drugs of today (Barcelona, Spain : 1998)* 51(2) (2015) 97-105.
- [164] **L. Calzetta**, A. Soggiu, P. Roncada, L. Bonizzi, E. Pistocchini, A. Urbani, B. Rinaldi, M.G. Matera, Propofol protects against opioid-induced hyperresponsiveness of airway smooth muscle in a horse model of target-controlled infusion anaesthesia, *European journal of pharmacology* 765 (2015) 463-71.
- [165] **L. Calzetta**, M.G. Matera, M. Cazzola, Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy, *European journal of pharmacology* 761 (2015) 168-73.
- [166] **L. Calzetta**, L. Luongo, M. Cazzola, C. Page, P. Rogliani, F. Facciolo, S. Maione, A. Capuano, B. Rinaldi, M.G. Matera, Contribution of sensory nerves to LPS-induced hyperresponsiveness of human isolated bronchi, *Life sciences* 131 (2015) 44-50.
- [167] **L. Calzetta**, M. Cazzola, C.P. Page, P. Rogliani, F. Facciolo, M.G. Matera, Pharmacological characterization of the interaction between the dual phosphodiesterase (PDE) 3/4 inhibitor RPL554 and glycopyrronium on human isolated bronchi and small airways, *Pulmonary pharmacology & therapeutics* 32 (2015) 15-23.
- [168] A. Segreti, **L. Calzetta**, P. Rogliani, M. Cazzola, Umeclidinium for the treatment of chronic obstructive pulmonary disease, *Expert review of respiratory medicine* 8(6) (2014) 665-71.
- [169] P. Rossi, P. Bove, M. Montuori, A. De Majo, E. Ricciardi, M. Mattei, R. Bernardini, **L. Calzetta**, P. Mauti, L. Intini, V. Quattrini, C. Chiaramonte, G. Vespasiani, Partial nephrectomy using radiofrequency incremental bipolar generator with multi electrode probe: experimental study in bench pig kidneys, *BMC urology* 14 (2014) 7.
- [170] P. Rogliani, **L. Calzetta**, A. Segreti, A. Barrile, M. Cazzola, Diabetes mellitus among outpatients with COPD attending a university hospital, *Acta diabetologica* 51(6) (2014) 933-40.
- [171] M.G. Matera, P. Rogliani, **L. Calzetta**, M. Cazzola, Phosphodiesterase inhibitors for chronic obstructive pulmonary disease: what does the future hold?, *Drugs* 74(17) (2014) 1983-92.
- [172] M.G. Matera, **L. Calzetta**, P. Rogliani, A. Cesario, M. Cazzola, New treatments for COPD in the elderly, *Current pharmaceutical design* 20(38) (2014) 5968-82.
- [173] R. Lipsi, P. Rogliani, **L. Calzetta**, A. Segreti, M. Cazzola, The clinical use of regenerative therapy in COPD, *International journal of chronic obstructive pulmonary disease* 9 (2014) 1389-96.
- [174] M. Cazzola, **L. Calzetta**, C.P. Page, P. Rogliani, F. Facciolo, A. Gavaldà, M.G. Matera, Pharmacological characterization of the interaction between acclidinium bromide and formoterol fumarate on human isolated bronchi, *European journal of pharmacology* 745 (2014) 135-43.
- [175] M. Cazzola, **L. Calzetta**, C.P. Page, M.G. Matera, Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation, *Expert opinion on drug metabolism & toxicology* 10(1) (2014) 129-37.
- [176] **L. Calzetta**, P. Rossi, P. Bove, P. Alfonsi, L. Bonizzi, P. Roncada, R. Bernardini, E. Ricciardi, M. Montuori, E. Pistocchini, P. Mauti, M. Mattei, Novel and effective balanced intravenous-inhalant anaesthetic protocol in swine by using unrestricted drugs, *Experimental animals* 63(4) (2014) 423-33.
- [177] **L. Calzetta**, P. Rogliani, M. Cazzola, M.G. Matera, Advances in asthma drug discovery: evaluating the potential of nasal cell sampling and beyond, *Expert opinion on drug discovery* 9(6) (2014) 595-607.
- [178] **L. Calzetta**, D. Passeri, V. Kanabar, P. Rogliani, C. Page, M. Cazzola, M.G. Matera, A. Orlandi, Brain natriuretic peptide protects against hyperresponsiveness of human asthmatic airway smooth muscle via an epithelial cell-dependent mechanism, *American journal of respiratory cell and molecular biology* 50(3) (2014) 493-501.
- [179] A. Segreti, E. Fiori, **L. Calzetta**, M. Sabatini, V. Segreti, P. Rogliani, M. Cazzola, The effect of indacaterol during an acute exacerbation of COPD, *Pulmonary pharmacology & therapeutics* 26(6) (2013) 630-4.
- [180] P. Rogliani, **L. Calzetta**, E.A. Rendina, D. Massullo, M. Dauri, B. Rinaldi, A. Capuano, M.G. Matera, The influence of propofol, remifentanyl and lidocaine on the tone of human bronchial smooth muscle, *Pulmonary pharmacology & therapeutics* 26(3) (2013) 325-31.
- [181] J. Ora, **L. Calzetta**, G. Pezzuto, L. Senis, G. Paone, A. Mari, S. Portalone, P. Rogliani, E. Puxeddu, C. Saltini, A 6MWT index to predict O2 flow correcting exercise induced SpO2 desaturation in ILD, *Respiratory medicine* 107(12) (2013) 2014-21.
- [182] M.G. Matera, **L. Calzetta**, D. Passeri, P. Rogliani, A. Orlandi, Epithelial-smooth muscle cooperation is needed for brain natriuretic peptide-dependent bronchorelaxant activity, *Pulmonary pharmacology & therapeutics* 26(1) (2013) 156-7.
- [183] M.G. Matera, **L. Calzetta**, M. Cazzola,  $\beta$ -Adrenoceptor modulation in chronic obstructive pulmonary disease: present and future perspectives, *Drugs* 73(15) (2013) 1653-63.

- [184] L.G. Franciosi, Z. Diamant, K.H. Banner, R. Zuiker, N. Morelli, I.M. Kamerling, M.L. de Kam, J. Burggraaf, A.F. Cohen, M. Cazzola, **L. Calzetta**, D. Singh, D. Spina, M.J. Walker, C.P. Page, Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials, *The Lancet. Respiratory medicine* 1(9) (2013) 714-27.
- [185] M. Cazzola, A. Segreti, **L. Calzetta**, P. Rogliani, Comorbidities of asthma: current knowledge and future research needs, *Current opinion in pulmonary medicine* 19(1) (2013) 36-41.
- [186] M. Cazzola, **L. Calzetta**, D. Lauro, G. Bettoncelli, C. Cricelli, N. Di Daniele, P. Rogliani, Asthma and COPD in an Italian adult population: role of BMI considering the smoking habit, *Respiratory medicine* 107(9) (2013) 1417-22.
- [187] **L. Calzetta**, C.P. Page, D. Spina, M. Cazzola, P. Rogliani, F. Facciolo, M.G. Matera, Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone, *The Journal of pharmacology and experimental therapeutics* 346(3) (2013) 414-23.
- [188] F. Pasqua, A. Alesii, K. Geraneo, S. Di Toro, G. La Torre, A. Sferrazza, M.G. Mastrullo, **L. Calzetta**, S. Bonassi, V. Cardaci, A. Cesario, A pilot survey on the quality of life in respiratory rehabilitation carried out in COPD patients with severe respiratory failure: preliminary data of a novel Inpatient Respiratory Rehabilitation Questionnaire (IRRQ), *Multidisciplinary respiratory medicine* 7(1) (2012) 46.
- [189] M.G. Matera, **L. Calzetta**, A. Segreti, M. Cazzola, Emerging drugs for chronic obstructive pulmonary disease, *Expert opinion on emerging drugs* 17(1) (2012) 61-82.
- [190] M.G. Matera, **L. Calzetta**, B. Rinaldi, M. Cazzola, Treatment of COPD: moving beyond the lungs, *Current opinion in pharmacology* 12(3) (2012) 315-22.
- [191] C.A. Hewson, S. Patel, **L. Calzetta**, H. Campwala, S. Havard, E. Luscombe, P.A. Clarke, P.T. Peachell, M.G. Matera, M. Cazzola, C. Page, W.M. Abraham, C.M. Williams, J.D. Clark, W.L. Liu, N.P. Clarke, M. Yeadon, Preclinical evaluation of an inhibitor of cytosolic phospholipase A2 $\alpha$  for the treatment of asthma, *The Journal of pharmacology and experimental therapeutics* 340(3) (2012) 656-65.
- [192] M. Cazzola, C.P. Page, **L. Calzetta**, M.G. Matera, Emerging anti-inflammatory strategies for COPD, *The European respiratory journal* 40(3) (2012) 724-41.
- [193] M. Cazzola, C.P. Page, **L. Calzetta**, M.G. Matera, Pharmacology and therapeutics of bronchodilators, *Pharmacological reviews* 64(3) (2012) 450-504.
- [194] M. Cazzola, **L. Calzetta**, P. Rogliani, D. Lauro, L. Novelli, C.P. Page, V. Kanabar, M.G. Matera, High glucose enhances responsiveness of human airways smooth muscle via the Rho/ROCK pathway, *American journal of respiratory cell and molecular biology* 47(4) (2012) 509-16.
- [195] M. Cazzola, **L. Calzetta**, G. Bettoncelli, C. Cricelli, F. Romeo, M.G. Matera, P. Rogliani, Cardiovascular disease in asthma and COPD: a population-based retrospective cross-sectional study, *Respiratory medicine* 106(2) (2012) 249-56.
- [196] M.G. Matera, **L. Calzetta**, P. Rogliani, F. Bardaro, C.P. Page, M. Cazzola, Evaluation of the effects of the R- and S-enantiomers of salbutamol on equine isolated bronchi, *Pulmonary pharmacology & therapeutics* 24(2) (2011) 221-6.
- [197] M.G. Matera, **L. Calzetta**, D. Passeri, F. Facciolo, E.A. Rendina, C. Page, M. Cazzola, A. Orlandi, Epithelium integrity is crucial for the relaxant activity of brain natriuretic peptide in human isolated bronchi, *British journal of pharmacology* 163(8) (2011) 1740-54.
- [198] M. Cazzola, A. Segreti, G. Bettoncelli, **L. Calzetta**, C. Cricelli, F. Pasqua, P. Rogliani, Change in asthma and COPD prescribing by Italian general practitioners between 2006 and 2008, *Primary care respiratory journal : journal of the General Practice Airways Group* 20(3) (2011) 291-8.
- [199] M. Cazzola, E. Puxeddu, G. Bettoncelli, L. Novelli, A. Segreti, C. Cricelli, **L. Calzetta**, The prevalence of asthma and COPD in Italy: a practice-based study, *Respiratory medicine* 105(3) (2011) 386-91.
- [200] M. Cazzola, **L. Calzetta**, C.P. Page, B. Rinaldi, A. Capuano, M.G. Matera, Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi, *American journal of respiratory cell and molecular biology* 45(4) (2011) 704-10.
- [201] M. Cazzola, **L. Calzetta**, M.G. Matera,  $\beta(2)$ -adrenoceptor agonists: current and future direction, *British journal of pharmacology* 163(1) (2011) 4-17.
- [202] M. Cazzola, **L. Calzetta**, G. Bettoncelli, L. Novelli, C. Cricelli, P. Rogliani, Asthma and comorbid medical illness, *The European respiratory journal* 38(1) (2011) 42-9.
- [203] **L. Calzetta**, D. Spina, M. Cazzola, C.P. Page, F. Facciolo, E.A. Rendina, M.G. Matera, Pharmacological characterization of adenosine receptors on isolated human bronchi, *American journal of respiratory cell and molecular biology* 45(6) (2011) 1222-31.
- [204] S.A. Tannu, L.M. Renzetti, N. Tare, J.D. Ventre, D. Lavelle, T.A. Lin, A. Morschauser, J. Paciorek, D.R. Bolin, H. Michel, L. Singer, M. Hargaden, I. Knowles, P. Gardiner, M. Cazzola, **L. Calzetta**, M.G. Matera, A. Hicks, Dual bronchodilatory and pulmonary anti-inflammatory activity of RO5024118, a novel agonist at vasoactive intestinal peptide VPAC2 receptors, *British journal of pharmacology* 161(6) (2010) 1329-42.
- [205] M.G. Matera, **L. Calzetta**, M. Cazzola, TNF-alpha inhibitors in asthma and COPD: we must not throw the baby out with the bath water, *Pulmonary pharmacology & therapeutics* 23(2) (2010) 121-8.
- [206] M. Cazzola, **L. Calzetta**, M.G. Matera, The cardiovascular risk of tiotropium: is it real?, *Expert opinion on drug safety* 9(5) (2010) 783-92.
- [207] M.G. Matera, **L. Calzetta**, V. Parascandolo, G. Curradi, P. Rogliani, M. Cazzola, Relaxant effect of brain natriuretic peptide in nonsensitized and passively sensitized isolated human bronchi, *Pulmonary pharmacology & therapeutics* 22(6) (2009) 478-82.
- [208] M.G. Matera, **L. Calzetta**, A. Sanduzzi, C.P. Page, M. Cazzola, Effects of neuraminidase on equine isolated bronchi, *Pulmonary pharmacology & therapeutics* 21(4) (2008) 624-9.
- [209] M.G. Matera, **L. Calzetta**, A. Peli, A. Scagliarini, C. Matera, M. Cazzola, Immune sensitization of equine bronchus: glutathione, IL-1 $\beta$  expression and tissue responsiveness, *Respiratory research* 6(1) (2005) 104.

[210] L. Calzetta, M. Cavaliere, E. Ruggeri, A. Ricci, G. Crescenzo, M. Amorena, Incidence of intentional poisoning of dogs in the Abruzzo region of Italy, Veterinary and human toxicology 44(2) (2002) 111-3.

Rome, December 19, 2020

Luigino Calzetta